Trading

Data

Solutions

Insights

Rgenix Stock

rgenix.comHealthcareFounded: 2010Funding to Date: $83.5MM

Rgenix is a developer of first-in-class drugs that target key pathways in cancer progression.

Buy or sell Rgenix stock Learn more about Rgenix IPO

Overview Financings Valuation

Enterprise Value (based on primary financings)

View Enterprise Value for Rgenix.

Register Today

Team

Management Team

Robert Wasserman MD

Chief Medical Officer

David Darst

Chief Operating Officer & Board Observer

Masoud Tavazoie Ph.D

Co-Founder, Board Member and Chief Executive Officer

Roger Waltzman MD

Chief Medical Officer

Sohail Tavazoie Ph.D

Co-Founder, Scientific & Clinical Advisor

Eric Rowinsky MD

Board Member & President

Board Members

David Darst

Noam Ohana

Conegliano Ventures

Saeed Tavazoie Ph.D

Eric Rowinsky MD

Nilesh Kumar Ph.D

Novo Holdings

Antoine Papiernik

Sofinnova Partners

Masoud Tavazoie Ph.D

Nancy Chang Ph.D

Peter Van Vlasselaer Ph.D

Other companies like Rgenix in the Healthcare sector

Altos Labs

Sector

Healthcare

Last Round Est. Valuation

$3.67B

Acelyrin

Sector

Healthcare

Last Round Est. Valuation

$809.52MM

Colossal Biosciences

Sector

Healthcare

Last Round Est. Valuation

$1.01B

Sector

Sector

Last Round Est. Valuation

$4.26B

Sector

Sector

Last Round Est. Valuation

$396.01MM

Synchron

Sector

Healthcare

Last Round Est. Valuation

$400.53MM

Alzheon

Sector

Healthcare

Last Round Est. Valuation

$1.53B

News

Business Wire 09/16/2019

Rgenix Names Industry Veteran to Chief Medical Officer Role

Rgenix, Inc. announced today that industry veteran Robert Wasserman, MD, has joined the Rgenix management team as its new Chief Medical Officer.

Business Wire 10/09/2018

Rgenix Raises $40M in Series C Funding To Support Clinical Stage Oncology Programs

Rgenix announces $40 million in a Series C financing in support of further development of the company’s clinical and pre-clinical oncology programs.

Popular Topics

Popular Topics

Rgenix Stock

Register for Details